Cagrilintide vs Cotadutide

Cagrilintide and Cotadutide represent two distinct classes of metabolic peptides under investigation for obesity and metabolic disorders. Cagrilintide, a long-acting amylin analog, targets satiety pathways via hindbrain circuits, while Cotadutide, a dual GLP-1/glucagon receptor agonist, combines glucose regulation with hepatic fat oxidation. Their evidence bases differ markedly: Cagrilintide has advanced to Phase III trials with robust weight loss data, whereas Cotadutide's development is less certain after mixed Phase II results. This comparison examines their mechanisms, research applications, and safety profiles to guide informed peptide selection.

Cagrilintide is a synthetic analog of human amylin, a hormone co-secreted with insulin by pancreatic beta cells, and is developed by Novo Nordisk as both a standalone agent and in combination with semaglutide (CagriSema). Its mechanism involves activating amylin receptors in the hindbrain to enhance satiety and reduce food intake, complementing GLP-1 pathways. The REDEFINE Phase III program reported that CagriSema achieved 20.4% weight loss at 68 weeks, surpassing semaglutide alone. Novo Nordisk filed for FDA approval in 2026, indicating strong evidence for efficacy. Research suggests that Cagrilintide's long-acting profile supports weekly dosing, improving compliance in preclinical models.

Cotadutide (MEDI0382) is a once-daily dual GLP-1/glucagon receptor agonist developed by AstraZeneca. It stimulates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression, while activating glucagon receptors to promote hepatic fat oxidation and energy expenditure. Phase II trials in type 2 diabetes, obesity, and NASH/MASH showed reductions in liver fat and glycemic improvements, but mixed results—including modest weight loss—led to uncertain development status after AstraZeneca's portfolio reprioritization. Studies indicate that Cotadutide's dual mechanism may offer unique benefits for hepatic steatosis, but its once-daily dosing and peak-trough fluctuations may increase gastrointestinal side effects compared to weekly formulations.

Both Cagrilintide and Cotadutide are investigated for weight management and metabolic health, including obesity and type 2 diabetes. Cagrilintide's research primarily focuses on weight loss, often in combination with semaglutide, with no unique applications beyond metabolic disorders. Cotadutide is additionally studied for non-alcoholic steatohepatitis (NASH/MASH) due to its glucagon-mediated effects on hepatic fat oxidation. Researchers should note that while both peptides target metabolic pathways, Cotadutide's liver-specific actions may be more relevant for hepatic research, whereas Cagrilintide's amylin-based satiety mechanism is distinct for appetite regulation studies.

Cagrilintide, particularly in CagriSema, shows gastrointestinal adverse events in 79.6% of subjects versus 39.9% with placebo, including nausea, vomiting, diarrhea, and constipation. These events are typically transient and mild-to-moderate, but pancreatitis, gallbladder events, and thyroid C-cell tumors (in rodents) mirror GLP-1 class risks. Cotadutide's safety profile includes dose-dependent GI side effects such as nausea, vomiting, and decreased appetite, common to GLP-1 agonists. Once-daily dosing may exacerbate these due to peak-trough fluctuations, though titration improves tolerability. Researchers must weigh these profiles: Cagrilintide's higher GI incidence is offset by weekly dosing, while Cotadutide's daily regimen may require more careful dose escalation.